Login / Signup

Cardiovascular Proteomics: A Post Hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist vs GnRH Agonist among Men with Advanced Prostate Cancer.

Lifshitz KarinYaara BerShenhar ChenJan NillsonAvivit PeerEli RosenbaumJack BanielDaniel KedarOsnat Itzhaki Ben ZadokDavid Margel
Published in: The Journal of urology (2021)
We compared longitudinal changes in CV proteins among men using androgen deprivation therapy. Our results support a direct protective effect of GnRH antagonist on plaque stability rather than a hazardous consequence of GnRH agonists on plaque rupture. This is a hypothesis generating study, and requires further confirmation.
Keyphrases
  • phase ii
  • prostate cancer
  • clinical trial
  • coronary artery disease
  • open label
  • middle aged
  • mass spectrometry
  • stem cells
  • double blind
  • label free
  • replacement therapy